Persistent Asthma Clinical Trial
Official title:
A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma
The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.
This was a stratified, randomized, open-label, active drug-controlled Phase 3 study. Patients who met all of the inclusion criteria and none of the exclusion criteria at the screening visit completed a 14 day (±2 days) pretreatment run in period. During the run-in period, patients continued using their current asthma medications (ie, inhaled corticosteroid and/or other controller therapies) except for their SABA, which was replaced by the sponsor-provided albuterol (salbutamol) hydrofluoroalkane (HFA) inhaler to be used as needed for symptomatic relief of asthma symptoms during the run in and treatment periods. Patients were assigned to inhaled corticosteroid (ICS) monotherapy or inhaled corticosteroid/long acting beta2 agonist (ICS/LABA) combination therapy and then to a mid- or high-treatment strength based on their current asthma maintenance therapy regimen. Patients in each strength of the ICS monotherapy cohort were randomly assigned in a 3:1 distribution to either the Fp MDPI or FLOVENT HFA treatment arm. Patients in each strength of the ICS/LABA combination cohort were randomly assigned in a 3:1 distribution to either the FS MDPI or ADVAIR DISKUS treatment arm. There was a total of 8 treatment arms following randomization. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02513160 -
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
|
Phase 3 | |
| Active, not recruiting |
NCT02883530 -
Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study
|
||
| Completed |
NCT02003521 -
Impact of Lung Flute Therapy on Asthma
|
N/A | |
| Completed |
NCT01253603 -
Efficacy, Safety, and Pharmacokinetics of QAW039
|
Phase 2 | |
| Completed |
NCT01845025 -
Study of Safety of Foradil in Patients With Persistent Asthma
|
Phase 4 | |
| Not yet recruiting |
NCT02053402 -
Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital
|
Phase 4 | |
| Completed |
NCT01156844 -
Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol
|
Phase 2 | |
| Completed |
NCT01078688 -
Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma
|
N/A | |
| Completed |
NCT02176694 -
Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care
|
N/A | |
| Completed |
NCT02026336 -
E-nose and Inflammatory Asthma Phenotypes
|
N/A | |
| Withdrawn |
NCT04271839 -
Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients
|
Phase 4 | |
| Active, not recruiting |
NCT04480242 -
Asthma Research in Children and Adolescents
|
||
| Completed |
NCT01147510 -
Asthma Control in Elderly Patients With Montelukast
|
Phase 4 | |
| Completed |
NCT03541187 -
Cockroach Immunotherapy in Children and Adolescents
|
Phase 2 | |
| Completed |
NCT02040779 -
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
|
Phase 3 | |
| Active, not recruiting |
NCT05843045 -
Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma
|
N/A |